The EP Migraine Alliance is n Alliance of Members of the European Parliament advocating to make migraine a European priority and improve the lives of people living with migraine across the European Union.
Watch the first webinar for patients on Covid-19 and its impact on migraine and other headaches streamed by Vall d’Hebron Hospital with the support of EMHA.
Learn about the impact of the virus on patients with migraine, the possible risks associated with the treatments and advice on reducing the negative impact of the lock down during migraine and other headaches episodes.
EMHA’s agenda of 2019 was fulfilled with activities, meetings and actions under the campaign name of #LightToMigraine. Read the full activities report. Go to the publications section to see the complete report.
European survey on migraine in the workplace. Analysis of results and conclusions. The objective of this study is to know the situation of migraine workers within the workplace and compare the situation in the different participating countries. Read de complete document in our Study section
EMHA and Allergan : Elena Ruiz de la Torre, Executive Director of EMHA attended a business meeting on 23 January with the Allergan Company. The purpose of the meeting was to share ideas and priorities to explore areas of collaboration and identify opportunities between EMHA and Allergan. We also took the opportunity to share …
European survey on migraine at work. Analysis of results and conclusions. The objective of this study is to know the situation of migraine workers within the workplace and compare the situation in the different participating countries. View the whole study
Each year, September 12th is the European Migraine Day of Action. Today, EMHA’s President and Executive Director have been invited by MEP Esteban Gonzalez Pons and MEP Dolors Montserrat to the European Parliament to discuss about how to better help the affected ones to give light to the disease and how to improve the life …
European Migraine Day of Action with MEPS in the European Parliament Read More »
Elena Ruiz de la Torre, presented at the IHC the movement #LightToMigraine, an initiative to
mobilize and activate the Affected Migraine community and show how extraordinary they are.
Nancy Baum Lipsitz remembers the night the pain began. She’d had a glass of white wine with a friend and went to bed with a terrible headache. The next day, she still felt horrible, the beginning of what she called a “rolling tide” of near constant migraines and lower level headaches. For three years she …
New drugs, decades in the making, are providing relief for migraines. Read More »
Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes …
“Green light” to Lilly’s monoclonal antibody to migraine Read More »
